Related Experiment Video
Updated: Oct 8, 2025
14:35
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
8.7K
Apolipoprotein E Polymorphism, Cardiac Remodeling, and Heart Failure in the ARIC Study
Senthil Selvaraj1, Brian Claggett2, Michelle C Johansen3
1Division of Cardiology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
Journal of Cardiac Failure
|December 29, 2021
Summary
The apolipoprotein E (APOE) ε4 gene variant, linked to Alzheimer's disease, does not increase the risk of heart failure (HF) or affect cardiac function. This study found no association between APOE ε4 and HF prevalence or severity.
Area of Science:
- Cardiology
- Neurology
- Genetics
Background:
- Beta-amyloid (Aβ) peptides found in the heart muscle of Alzheimer's disease (AD) patients raise questions about cardiac implications.
- The apolipoprotein E (APOE) ε4 allele is a known genetic risk factor for AD.
Purpose of the Study:
- To investigate the association between the APOE ε4 genotype and heart failure (HF).
- To examine the relationship between APOE ε4 and cardiac structure, function, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels.
Main Methods:
- A large cohort study (15,064 participants) analyzed genotype status and incident HF hospitalizations using Cox regression.
- Biomarkers (NT-proBNP) and cardiac parameters were assessed across multiple visits.
- Aβ peptide levels were also related to incident HF.
Main Results:
- No significant difference in prevalent heart failure (HF) was observed based on APOE ε4 genotype.
- APOE ε4 carriers did not show an increased risk for HF hospitalization.
- Cardiac structure, function, and NT-proBNP levels were not associated with the APOE ε4 genotype.
Conclusions:
- The APOE ε4 genotype, a risk factor for Alzheimer's disease, is not linked to a higher prevalence of heart failure.
- Genetic predisposition to AD via APOE ε4 does not correlate with increased myocardial remodeling or biochemical markers of HF.
Related Concept Videos
01:30Coronary Artery Disease I: Introduction
376
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
376
01:26Atherosclerosis III: Management
62
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
62
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
251
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
251
01:17Pathophysiology of Heart Failure
2.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.0K
01:26Coronary Artery Disease II: Pathophysiology
76
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
76
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
86
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
86